We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A group of House Democrats has sent a letter to HHS Secretary Michael Leavitt demanding an explanation of former FDA commissioner Mark McClellan’s role in the agency’s controversial handling of Barr Laboratories’ emergency contraceptive Plan B.
Manufacturer-sponsored patient assistance programs (PAPs) for Medicare Part D enrollees pose heightened fraud risks and must be phased out by 2007, the HHS Office of the Inspector General (OIG) said.
Manufacturer-sponsored patient assistance programs (PAPs) for Medicare Part D enrollees pose heightened fraud risks and must be phased out by 2007, the HHS Office of the Inspector General (OIG) said.
Two influential Senate Republicans offered an amendment to a federal spending bill yesterday calling for nearly $4 billion in funding for pandemic flu preparation.
President Bush last week unveiled his strategy to prevent a flu pandemic — a plan that includes developing new methods of manufacturing flu vaccine, as well as better liability protection for U.S. manufacturers to encourage domestic vaccine production.
The HHS Inspector General (IG) has agreed to investigate the reasons behind former FDA Commissioner Lester Crawford's sudden resignation in response to inquiries from a bipartisan coalition of lawmakers.
The HHS Inspector General (IG) has agreed to investigate the reasons behind former FDA Commissioner Lester Crawford’s sudden resignation in response to inquiries from a bipartisan coalition of lawmakers.
The HHS has awarded Chiron a $62.5 million contract to supply pre-pandemic influenza vaccine for a federal stockpile to protect against the H5N1 avian influenza virus strain.
The Office of Human Research Protections (OHRP) has issued guidance to institutional review boards (IRBs) for reviewing information provided on clinical trial websites.
Sen. Ron Wyden (D-Ore.) claims his proposal calling for the government to directly negotiate Medicare drug prices with manufacturers has amassed enough votes to pass the Senate, but congressional sources are skeptical that anything has changed since the bill was narrowly defeated in March.